Comparison of Serum Changes of Interleukin-17A and Interleukin-21 Between Schizophrenic Patients and Healthy Individuals.

IF 1.6 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Reports of Biochemistry and Molecular Biology Pub Date : 2022-10-01 DOI:10.52547/rbmb.11.3.465

Seyed Ali Miresmaeili Mazrakhondi, Hadi Zare-Zardini

{"title":"Comparison of Serum Changes of Interleukin-17A and Interleukin-21 Between Schizophrenic Patients and Healthy Individuals.","authors":"Seyed Ali Miresmaeili Mazrakhondi, Hadi Zare-Zardini","doi":"10.52547/rbmb.11.3.465","DOIUrl":null,"url":null,"abstract":"Background: Immunological alterations in schizophrenic patients have been considered during last decade. There are no remarkable reports on the changes of IL-17A and IL-21 in schizophrenic patients. Therefore, the purpose of this study was to evaluate changes of serum IL-17A and IL-21 in schizophrenic patients in comparison with healthy controls.Methods: In the present study serum levels of IL-17A and IL-21 in 30 patients with schizophrenia before treatment and three months after treatment were measured by enzyme-linked immunosorbent assay (ELISA) and compare to 30 match healthy control group.Results: Serum levels of IL-21 in schizophrenic patient was significantly higher than control group (P= 0.001). Serum levels of IL-17A in the schizophrenic patients had no significant changes than the control group (P= 0.4). Serum levels of IL-17A in patients with schizophrenia three months after treatment than before treatment had no significant change (P=0.7) and IL-21 serum levels in schizophrenic patient three month after treatment was not significant changed in comparison with this group before treatment (P= 0.06).Conclusion: The serum levels of interlukine-21 is elevated in schizophrenic. Results of this study showed that IL-21 might be involved in the pathologic mechanism of schizophrenia.","PeriodicalId":45319,"journal":{"name":"Reports of Biochemistry and Molecular Biology","volume":"11 3","pages":"465-470"},"PeriodicalIF":1.6000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883033/pdf/rbmb-11-465.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Biochemistry and Molecular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52547/rbmb.11.3.465","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Immunological alterations in schizophrenic patients have been considered during last decade. There are no remarkable reports on the changes of IL-17A and IL-21 in schizophrenic patients. Therefore, the purpose of this study was to evaluate changes of serum IL-17A and IL-21 in schizophrenic patients in comparison with healthy controls.

Methods: In the present study serum levels of IL-17A and IL-21 in 30 patients with schizophrenia before treatment and three months after treatment were measured by enzyme-linked immunosorbent assay (ELISA) and compare to 30 match healthy control group.

Results: Serum levels of IL-21 in schizophrenic patient was significantly higher than control group (P= 0.001). Serum levels of IL-17A in the schizophrenic patients had no significant changes than the control group (P= 0.4). Serum levels of IL-17A in patients with schizophrenia three months after treatment than before treatment had no significant change (P=0.7) and IL-21 serum levels in schizophrenic patient three month after treatment was not significant changed in comparison with this group before treatment (P= 0.06).

Conclusion: The serum levels of interlukine-21 is elevated in schizophrenic. Results of this study showed that IL-21 might be involved in the pathologic mechanism of schizophrenia.

查看原文本刊更多论文

精神分裂症患者与健康人群血清白细胞介素- 17a和白细胞介素-21变化的比较

背景:在过去的十年中，精神分裂症患者的免疫学改变已经被考虑。IL-17A和IL-21在精神分裂症患者中的变化尚未见报道。因此，本研究的目的是评估精神分裂症患者血清IL-17A和IL-21的变化，并与健康对照进行比较。方法:采用酶联免疫吸附试验(ELISA)检测30例精神分裂症患者治疗前和治疗后3个月血清IL-17A和IL-21水平，并与30例匹配的健康对照组进行比较。结果:精神分裂症患者血清IL-21水平显著高于对照组(P= 0.001)。精神分裂症患者血清IL-17A水平与对照组比较差异无统计学意义(P= 0.4)。精神分裂症患者治疗3个月后血清IL-17A水平与治疗前比较无显著变化(P=0.7)，治疗3个月后血清IL-21水平与治疗前比较无显著变化(P= 0.06)。结论:精神分裂症患者血清白介素-21水平升高。本研究结果提示IL-21可能参与了精神分裂症的病理机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reports of Biochemistry and Molecular Biology BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.80

自引率

23.50%

发文量

审稿时长

10 weeks

期刊介绍： The Reports of Biochemistry & Molecular Biology (RBMB) is the official journal of the Varastegan Institute for Medical Sciences and is dedicated to furthering international exchange of medical and biomedical science experience and opinion and a platform for worldwide dissemination. The RBMB is a medical journal that gives special emphasis to biochemical research and molecular biology studies. The Journal invites original and review articles, short communications, reports on experiments and clinical cases, and case reports containing new insights into any aspect of biochemistry and molecular biology that are not published or being considered for publication elsewhere. Publications are accepted in the form of reports of original research, brief communications, case reports, structured reviews, editorials, commentaries, views and perspectives, letters to authors, book reviews, resources, news, and event agenda.